Roth/MKM analyst Jonathan Aschoff reiterated a Buy rating and $30.00 price target on Moleculin Biotech (NASDAQ: MBRX).The analyst comments "Ending ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE